Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![MarketPulse360 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1517444811296587777.png) Market Pulse 360° [@MarketPulse360](/creator/twitter/MarketPulse360) on x XX followers
Created: 2025-07-17 22:14:56 UTC

Dr. Reddy's Launches Sanofi's Beyfortus® in India for RSV Prevention #DRREDDY $RDY



➡️ Dr. Reddy’s Laboratories has launched Beyfortus® (nirsevimab) in India, a preventive treatment for Respiratory Syncytial Virus (RSV) in infants, following an expanded partnership with Sanofi.

➡️ RSV is a significant, yet underreported, health crisis in India, causing many respiratory infections in infants with experts reporting over XXXXX child deaths in 2024 from Kolkata, Bengaluru, and Mumbai alone.

➡️ According to the Article, Beyfortus® launch aligns with Dr. Reddy's dual-track growth strategy, strengthening its core business and building new value through strategic partnerships, with vaccines significantly driving growth in India.

➡️ The distribution agreement builds upon Dr. Reddy’s successful vaccine partnership with Sanofi established in 2024 and its broader strategy of collaborations to bring innovation to India. These collaborations include ventures with Nestlé India, Gilead Sciences, and Takeda, among others.

➡️ Beyfortus® provides a preventive option to reduce hospitalizations and complications from RSV. Its introduction in India aligns the country’s preventive healthcare with global standards, as it is already approved in the EU, U.S., China, Japan, and other countries.
 

#NYSE

-- 
Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Dr Reddy’s Laboratories or a related party has paid Wall Street Wire for ongoing promotional services. Full disclosures: Our content is not financial advice.

![](https://pbs.twimg.com/card_img/1945965472135991296/KmuEMfzb?format=jpg&name=800x419)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945970502436020389/c:line.svg)

**Related Topics**
[$drreddyns](/topic/$drreddyns)
[india](/topic/india)
[dr reddys](/topic/dr-reddys)
[pulse](/topic/pulse)
[$rdy](/topic/$rdy)
[sanofi](/topic/sanofi)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/MarketPulse360/status/1945970502436020389)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

MarketPulse360 Avatar Market Pulse 360° @MarketPulse360 on x XX followers Created: 2025-07-17 22:14:56 UTC

Dr. Reddy's Launches Sanofi's Beyfortus® in India for RSV Prevention #DRREDDY $RDY

➡️ Dr. Reddy’s Laboratories has launched Beyfortus® (nirsevimab) in India, a preventive treatment for Respiratory Syncytial Virus (RSV) in infants, following an expanded partnership with Sanofi.

➡️ RSV is a significant, yet underreported, health crisis in India, causing many respiratory infections in infants with experts reporting over XXXXX child deaths in 2024 from Kolkata, Bengaluru, and Mumbai alone.

➡️ According to the Article, Beyfortus® launch aligns with Dr. Reddy's dual-track growth strategy, strengthening its core business and building new value through strategic partnerships, with vaccines significantly driving growth in India.

➡️ The distribution agreement builds upon Dr. Reddy’s successful vaccine partnership with Sanofi established in 2024 and its broader strategy of collaborations to bring innovation to India. These collaborations include ventures with Nestlé India, Gilead Sciences, and Takeda, among others.

➡️ Beyfortus® provides a preventive option to reduce hospitalizations and complications from RSV. Its introduction in India aligns the country’s preventive healthcare with global standards, as it is already approved in the EU, U.S., China, Japan, and other countries.

#NYSE

-- Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Dr Reddy’s Laboratories or a related party has paid Wall Street Wire for ongoing promotional services. Full disclosures: Our content is not financial advice.

XXX engagements

Engagements Line Chart

Related Topics $drreddyns india dr reddys pulse $rdy sanofi stocks healthcare

Post Link

post/tweet::1945970502436020389
/post/tweet::1945970502436020389